ATE214392T1 - Amid-analoge-derivate von bestimmten methanoverbrückten chinolizinen - Google Patents
Amid-analoge-derivate von bestimmten methanoverbrückten chinolizinenInfo
- Publication number
- ATE214392T1 ATE214392T1 AT92401618T AT92401618T ATE214392T1 AT E214392 T1 ATE214392 T1 AT E214392T1 AT 92401618 T AT92401618 T AT 92401618T AT 92401618 T AT92401618 T AT 92401618T AT E214392 T1 ATE214392 T1 AT E214392T1
- Authority
- AT
- Austria
- Prior art keywords
- chem
- treatment
- quinolicines
- methano
- bridged
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- -1 R2 is H Chemical group 0.000 abstract 1
- HCUOEKSZWPGJIM-YBRHCDHNSA-N (e,2e)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N/O)\C(N)=O HCUOEKSZWPGJIM-YBRHCDHNSA-N 0.000 abstract 1
- 102000035037 5-HT3 receptors Human genes 0.000 abstract 1
- 108091005477 5-HT3 receptors Proteins 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 abstract 1
- 101000598778 Homo sapiens Protein OSCP1 Proteins 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 101001067395 Mus musculus Phospholipid scramblase 1 Proteins 0.000 abstract 1
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000030135 gastric motility Effects 0.000 abstract 1
- 230000003400 hallucinatory effect Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000002636 symptomatic treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP91401550A EP0517984A1 (de) | 1991-06-11 | 1991-06-11 | Amidanaloge-Derivate von methanoverbrückten Chinolizinen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE214392T1 true ATE214392T1 (de) | 2002-03-15 |
Family
ID=8208580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92401618T ATE214392T1 (de) | 1991-06-11 | 1992-06-11 | Amid-analoge-derivate von bestimmten methanoverbrückten chinolizinen |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP0517984A1 (de) |
| JP (1) | JP3377227B2 (de) |
| KR (1) | KR100234926B1 (de) |
| AT (1) | ATE214392T1 (de) |
| AU (1) | AU649836B2 (de) |
| CA (1) | CA2070573C (de) |
| DE (1) | DE69232473T2 (de) |
| DK (1) | DK0518767T3 (de) |
| ES (1) | ES2173863T3 (de) |
| FI (1) | FI112866B (de) |
| HU (1) | HU212735B (de) |
| IE (1) | IE921874A1 (de) |
| IL (1) | IL102132A (de) |
| NO (1) | NO305124B1 (de) |
| NZ (1) | NZ243031A (de) |
| PT (1) | PT518767E (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508287A (en) * | 1992-02-24 | 1996-04-16 | Merrell Pharmaceuticals Inc. | 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist |
| EP0628043A1 (de) * | 1992-02-24 | 1994-12-14 | Merrell Pharmaceuticals Inc. | 216-methano-2h-quinolizine derivate als 5-ht3 rezeptor antagonist |
| GB9214184D0 (en) * | 1992-07-03 | 1992-08-12 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9304500D0 (en) * | 1993-03-05 | 1993-04-21 | Glaxo Spa | Heterocyclic compounds |
| GB9406857D0 (en) * | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| FR2765107B1 (fr) * | 1997-06-26 | 2000-03-24 | Sanofi Sa | Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil |
| DK1030667T3 (da) * | 1997-11-14 | 2005-06-20 | Akzo Nobel Nv | Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö |
| US7160898B2 (en) | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| CA2321900C (en) | 1998-02-27 | 2011-07-19 | The Board Of Trustees Of The University Of Illinois | Agents with serotonin-related activity for the treatment for sleep apnea |
| US7666867B2 (en) | 2001-10-26 | 2010-02-23 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
| CA2590802A1 (en) | 2004-12-20 | 2006-06-29 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| WO2007081890A2 (en) | 2006-01-05 | 2007-07-19 | Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Production of dolasetron |
| CN101774971B (zh) * | 2010-02-10 | 2011-07-27 | 山东众诚药业股份有限公司 | 高纯度1-甲基吲唑-3-羧酸的生产方法 |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| WO2024052684A1 (en) | 2022-09-09 | 2024-03-14 | MyricX Pharma Limited | Antibody drug conjugate comprising nmt inhibitor and its use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB219363A (en) * | 1923-03-24 | 1924-07-24 | Abraham Preston | Improvements in or in connection with bed couches |
| DE3650772T2 (de) * | 1985-04-27 | 2003-04-03 | F. Hoffmann-La Roche Ag, Basel | Derivate von Indazole-3-carboxamide und -3-carboxylsäure |
| EP0330788A1 (de) * | 1988-03-01 | 1989-09-06 | Merrell Dow Pharmaceuticals Inc. | Verwendung von Chinolizin- und Chinolizinon-Derivaten zur Herstellung von Arzneimitteln zur Behandlung von Herz-Arrhythmie |
| GB8829079D0 (en) * | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
-
1991
- 1991-06-11 EP EP91401550A patent/EP0517984A1/de not_active Withdrawn
-
1992
- 1992-06-05 CA CA002070573A patent/CA2070573C/en not_active Expired - Lifetime
- 1992-06-05 NZ NZ243031A patent/NZ243031A/en not_active IP Right Cessation
- 1992-06-05 AU AU18037/92A patent/AU649836B2/en not_active Expired
- 1992-06-08 IL IL10213292A patent/IL102132A/en not_active IP Right Cessation
- 1992-06-10 FI FI922695A patent/FI112866B/fi not_active IP Right Cessation
- 1992-06-10 NO NO922270A patent/NO305124B1/no not_active IP Right Cessation
- 1992-06-10 KR KR1019920010016A patent/KR100234926B1/ko not_active Expired - Lifetime
- 1992-06-10 HU HU9201939A patent/HU212735B/hu unknown
- 1992-06-11 DK DK92401618T patent/DK0518767T3/da active
- 1992-06-11 ES ES92401618T patent/ES2173863T3/es not_active Expired - Lifetime
- 1992-06-11 PT PT92401618T patent/PT518767E/pt unknown
- 1992-06-11 JP JP17598392A patent/JP3377227B2/ja not_active Expired - Lifetime
- 1992-06-11 DE DE69232473T patent/DE69232473T2/de not_active Expired - Lifetime
- 1992-06-11 AT AT92401618T patent/ATE214392T1/de active
- 1992-06-11 EP EP92401618A patent/EP0518767B1/de not_active Expired - Lifetime
- 1992-07-01 IE IE187492A patent/IE921874A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP3377227B2 (ja) | 2003-02-17 |
| FI922695A0 (fi) | 1992-06-10 |
| EP0518767B1 (de) | 2002-03-13 |
| AU649836B2 (en) | 1994-06-02 |
| NO305124B1 (no) | 1999-04-06 |
| HU9201939D0 (en) | 1992-08-28 |
| KR930000518A (ko) | 1993-01-15 |
| FI112866B (fi) | 2004-01-30 |
| HUT61549A (en) | 1993-01-28 |
| DE69232473T2 (de) | 2002-11-21 |
| NO922270D0 (no) | 1992-06-10 |
| PT518767E (pt) | 2002-09-30 |
| ES2173863T3 (es) | 2002-11-01 |
| KR100234926B1 (ko) | 1999-12-15 |
| CA2070573A1 (en) | 1992-12-12 |
| IL102132A0 (en) | 1993-01-14 |
| AU1803792A (en) | 1992-12-24 |
| EP0517984A1 (de) | 1992-12-16 |
| HU212735B (en) | 1996-10-28 |
| IL102132A (en) | 1996-10-31 |
| DE69232473D1 (de) | 2002-04-18 |
| JPH05202044A (ja) | 1993-08-10 |
| FI922695L (fi) | 1992-12-12 |
| EP0518767A2 (de) | 1992-12-16 |
| NZ243031A (en) | 1994-02-25 |
| NO922270L (no) | 1992-12-14 |
| DK0518767T3 (da) | 2002-07-01 |
| CA2070573C (en) | 2003-04-15 |
| EP0518767A3 (en) | 1993-05-05 |
| IE921874A1 (en) | 1992-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69232473D1 (de) | Amid-Analoge-Derivate von bestimmten methanoverbrückten Chinolizinen | |
| FI941378A0 (fi) | Bentsimidatsoliyhdisteitä, niiden käyttö ja valmistus | |
| NO981496L (no) | Imidazolderivater med affinitet for <alfa> 2 reseptoraktivitet | |
| ATE101140T1 (de) | Substituierte cycloalkanole. | |
| GR3026233T3 (en) | Therapeutic agents for use in the treatment of Parkinson's Disease | |
| NZ238956A (en) | 3-arylindole or 3-arylindazole derivatives and medicaments thereof. | |
| ZA928414B (en) | 2-heterocyclicethylamine derivatives and their use as pharmaceuticals. | |
| ES2182509T3 (es) | Derivados de n-ariloxietilamina para el tratamiento de la depresion. | |
| ATE161533T1 (de) | Imidanolon- und oxanolonderivate als dopaminantagonisten | |
| DK0489379T3 (da) | 5-Amino-5,6,7,8-tetrahydroquinoliner og beslægtede forbindelser, en fremgangsmåde til deres fremstilling og deres anvendels | |
| DK0451538T3 (da) | Anvendelse af pyridoindolderivater til behandling af iskæmiske lidelser | |
| PT889044E (pt) | Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central | |
| ATE186912T1 (de) | Carbamoylpyrrolidon-derivate zur behandlung von depressionen und cerebrovasculären störungen | |
| EP0543307A3 (en) | Nootropic agent | |
| ATE108444T1 (de) | 3-isoxazolonderivate, ihre herstellung und ihre anwendung in der therapeutik. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEIH | Change in the person of patent owner |